<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074550</url>
  </required_header>
  <id_info>
    <org_study_id>PPMX-T003-CT102</org_study_id>
    <nct_id>NCT05074550</nct_id>
  </id_info>
  <brief_title>Safety Evaluation Study for Patients With Polycythemia Vera</brief_title>
  <official_title>Phase I, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of A Single Intravenous PPMX-T003 in Polycythemia Vera</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perseus Proteomics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perseus Proteomics Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003&#xD;
      in Polycythemia Vera&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in the Study</measure>
    <time_frame>45 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics of PPMX-T003 after single dose</measure>
    <time_frame>Day1,Day2,Day7</time_frame>
    <description>Observed maximum plasma concentration [Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics of PPMX-T003 after single dose</measure>
    <time_frame>Day1,Day2,Day7</time_frame>
    <description>Terminal elimination rate constant [λz]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics of PPMX-T003 after single dose</measure>
    <time_frame>Day1,Day2,Day7</time_frame>
    <description>Area under the concentration-time curve from pre-dose [time 0] to the time of the last quantifiable concentration [AUC0-t]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics of PPMX-T003 after single dose</measure>
    <time_frame>Day1,Day2,Day7</time_frame>
    <description>Area under the concentration-time curve from pre-dose [time 0] extrapolated to infinite time [AUC0-inf]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics of PPMX-T003 after single dose</measure>
    <time_frame>Day1,Day2,Day7</time_frame>
    <description>Apparent terminal half-life [t½]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics of PPMX-T003 after single dose</measure>
    <time_frame>Day1,Day2,Day7</time_frame>
    <description>Apparent systemic clearance [CL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics of PPMX-T003 after single dose</measure>
    <time_frame>Day1,Day2,Day7</time_frame>
    <description>Volume of distribution [Vd]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examining the expression rate of anti-drug antibodies (ADA)</measure>
    <time_frame>Day1,Day21,up to 45weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>PPMX-T003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This drug should be administered within 48 hours after the phlebotomy. In addition, as a dose escalation design, 4 doses of 0.25 mg/kg, 0.4 mg/kg, 0.64 mg/kg, and 1 mg/kg are administered to the same subject, when the next phlebotomy required during observation period after the 1st administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPMX-T003</intervention_name>
    <description>As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.</description>
    <arm_group_label>PPMX-T003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of PV according to either the 2008 or 2016 WHO classification&#xD;
             criteria&#xD;
&#xD;
          -  PV patients being only treated with phlebotomy and the interval is 4-9 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients administrated drugs for PV treatment such as hydroxyurea or ruxolitinib&#xD;
             (aspirin is excluded)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tadashi Matsuura</last_name>
    <phone>+81-3-5738-1705</phone>
    <email>tmatsuura@ppmx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hiroko Akiyoshi</last_name>
    <phone>+81-3-5738-1705</phone>
    <email>hakiyoshi@ppmx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital</name>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloproliferative neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

